StockMarketWire.com - Deltex Medical Group is making good progress with sales up on a year ago on improved margins and lower operating costs, shareholders at today's annual general meeting will be told.

The group has also announced the publication of a new trial showing excellent results from using ODM in thoracic surgery.

It said the results of the randomised controlled trial of 100 patients undergoing lung surgery at the University of Freiburg in Germany had been published online by the British Journal of Anaesthesia.

Vascular fluids and vaso-active drugs were administered during surgery in accordance with Enhanced Recovery After Surgery Society recommended protocols. Nine fewer ODM patients (six v 15) suffered post-operative pulmonary complications and ODM patients had a two day shorter stay in hospital (nine v 11 days).

The group said this was the first published randomised controlled trial studying ODM use during thoracic surgery.

Chairman Nigel Keen will tell the AGM: "In the USA, our key development territory, we have continued both to add new accounts and increase probe revenues.

"In January we reached our target of 30 platform accounts and, since then, we have added a further two key accounts: a major University Hospital in our West Coast territory and, in the Mid-Atlantic territory, a large hospital in the prestigious Johns Hopkins network.

"In addition we are working to conclude the contracting process with two additional key accounts following successful evaluations and continue to develop the pipeline.

"US revenues for the five months to end of May increased over 40% compared to the same period in 2016.

"This growth includes the impact of a £0.1m monitor order in Q1 and foreign exchange tailwinds.

"We are in the process of redeploying our US field team to best support the platform programme accounts.

"March was the first month in which the margin on US probe revenues (excluding monitors) covered regular US staff costs and we are looking to broadly maintain this relationship as we add additional staff.

"US probe margin in May was sufficient to cover the costs of the two additional field staff added since March.

"Total regular monthly US staff costs in May were $220,000.

"Reducing towards zero the amount by which regular US staff costs exceed probe margin is a major contributory factor to the company's improved operating cash profile: the monthly excess of regular US staff costs over margin from probe sales has been funded out of equity during this phase of our US expansion plans and peaked at around $150,000 a month in 2015.

"Probe consumption in our International business is continuing to grow satisfactorily especially in our more developed focus markets and revenues after five months are marginally ahead of the prior year.

"Although we currently anticipate International sales to be ahead of management expectations for the first half, timing differences on large orders from our distributors in Peru and South Korea in 2016 make it likely that total first half International revenues will be lower than in 2016.

"In contrast with growing sales in export markets, the UK remains challenging.

"Year to date UK revenues at the end of May 2017 were slightly behind 2016 (c3%) having been slightly ahead in the first quarter reflecting delays in many NHS organisations setting budgets for their new financial year which started in April.

"Our UK business remains profitable and it is encouraging that it continues to stabilise: at the same stage in 2016, UK revenues were c25% behind the prior year.

"Our goal remains to get the UK business back into growth by the end of the year and we have been encouraged by the positive response to our new High Definition Impedance Cardiography (HD-ICG) product since its launch last month.

"Customers can add HD-ICG to their existing CardioQ-ODM+ monitors at low cost, and together with the existing ODM and Pulse Pressure Waveform Analysis functionality means we are now offering the three leading modern advanced haemodynamic monitoring technologies on a single platform.

"This gives us a unique offer and means that, for the first time, we can support demand for advanced haemodynamic monitoring across the whole hospital.

"We plan to launch HD-ICG to our International distributors in September and in the USA as soon as we receive FDA clearance.

"In the meantime we continue to differentiate the premium clinical effectiveness of ODM through clinical evidence and today announced the positive results from the first randomised controlled trial of ODM in thoracic surgery.

"The Company's key priority this year is to move the business through the cash break-even point at the operating level to enable us to continue to grow our business from our own internally generated resources.

" We have made significant progress towards this goal so far this year through growth in sales of existing products, manufacturing efficiencies and reduced overheads.

"Looking forward we expect to also start to generate cash returns from investments made in recently released new products as well as having a number of other exciting new product developments in hand."




Story provided by StockMarketWire.com